Skip to main content

Table 2 (abstract P24). Efficacy ─ 52-week OLE completers

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

Outcome Time-point Erenumab 70-mg (OLE last dose received) (N=266) Erenumab 140-mg (OLE last dose received) (N=203)
Change from baseline in MMD, mean (95% CI) Baseline 17.92 (17.38, 18.45) 17.79 (17.16, 18.43)
Week 40 -7.81 (-8.64, -6.97 ) (n=228) -9.96 (-10.91, -9.00 ) (n=187)
Week 52 -8.49 (-9.35, -7.63) (n=214) -10.48 (-11.52, -9.43) (n=165)
Change from baseline in MSMD, mean (95% CI) Baseline 10.22 (9.39, 11.06) 8.32 (7.28, 9.35)
Week 40 -4.68 (-5.33, -4.04) (n=228) -4.59 (-5.32, -3.85) (n=187)
Week 52 -5.05 (-5.76, -4.34) (n=214) -4.97 (-5.81, -4.13) (n=165)
Change from baseline in MSMD in subjects taking MSM, mean (95% CI) Baseline 12.40 (11.67, 13.13) 11.35 (10.30, 12.40)
Week 40 -5.63 (-6.33, -4.93) -6.15 (-7.00, -5.30)
Week 52 -6.16 (-6.93, -5.40) -6.71 (-7.67, -5.75)
≥50% responder rate, N1(%) Week 40 108 (47.4) (n=228) 126 (67.4) (n=187)
Week 52 114 (53.3) (n=214) 111 (67.3) (n=165)
  1. CI confidence interval, OLE open label extension, MMD monthly migraine days, MSMD migraine-specific medication treatment days, N number of subjects in the analysis set, N1 number of responders at corresponding visit, n number of subjects with observed data